Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/2004

01-02-2004 | Original Article

Phase II study of the combination of vinorelbine and cisplatin in advanced non-small-cell lung cancer

Authors: Kiyoshi Mori, Yukari Kamiyama, Tetsuro Kondo, Yasuhiko Kano, Keigo Tominaga

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2004

Login to get access

Abstract

Purpose

To evaluate the efficacy and safety of combination chemotherapy with cisplatin and vinorelbine for the treatment of previously untreated patients with advanced non-small-cell lung cancer (NSCLC).

Patients and methods

Eligible patients were those with measurable NSCLC. They were treated with two or more cycles of a regimen consisting of vinorelbine 25 mg/m2 on days 1 and 8 and cisplatin 80 mg/m2 on day 1 every 3 weeks.

Results

A total of 45 patients were enrolled. The response rate was 51.1% (23/45; 95% CI 35.8% to 66.3%). The median survival was 286 days with a 1-year survival rate of 40%. The median number of treatment cycles was 2. The major toxic effect was neutropenia of grade 3 or higher (84%). Nonhematological toxicities, including vomiting (62%), were mild (grade 2 or less). There were no treatment-related deaths.

Conclusion

The high response rate and good tolerability proved this combination therapy to be a safe and effective treatment for advanced NSCLC.
Literature
1.
Adam Z, Coupkova H, Kolek V, et al (1995) Vinorelbine and cisplatin in the treatment of advanced non-small-cell lung cancer: results of a multicenter Czech study. Acta Med Austriaca 22:120–124PubMed
2.
Berthaud P, Le Chevalier LT, Ruffie P, et al (1992) Phase I-II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer 28A:1863–1865PubMed
3.
Binet S, Fellous A, Lataste H, Krikorian A, Couzinier JP, Meininger V (1989) In situ analysis of the action of navelbine on various types of microtubules using immunofluorescence. Semin Oncol 16 [Suppl 4]:5–8
4.
Bretti S, Berruti A, Gorzegno G, et al (1996) Multicenter phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients. Lung Cancer 14:353–360CrossRefPubMed
5.
Canobbio L, Boccardo F, Pastorino G, et al (1989) Phase II study of Navelbine in advanced breast cancer. Semin Oncol 16 [Suppl 4]:33–36
6.
Chevalier TL, Brisgand D, Douillard JY, et al (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360–367PubMed
7.
Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC (1989) Efficacy of Navelbine (NVB) in non-small cell lung cancer (NSCLC). Semin Oncol 16 [Suppl 4]:26–29
8.
Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC (1991) A phase II study of Navelbine (vinorelbine) in the treatment of non-small cell lung cancer (NSCLC). Am J Clin Oncol 14:115–119PubMed
9.
Fellous A, Ohayon R, Vacassin T, et al (1989) Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol 16 [Suppl 4]:9–14
10.
Frontini L, Candido P, Cattaneo MT, et al (1996) Cisplatin-vinorelbine combination chemotherapy in locally advanced non-small cell lung cancer. Tumori 82:57–60PubMed
11.
Gebbia V, Caruso M, Valenza R, et al (1994) Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non-small cell lung carcinoma. Anticancer Res 14:1247–1250PubMed
12.
Gomi K, Ohno H, Nomura K, Okabe M, Kobayashi K, Niitani H (1986) Kinetic analysis of combination effect of Navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cell in culture. Jpn J Cancer Res 83:532–539
13.
Kusunoki Y, Furuse K, Yamori S, et al (1995) Randomized phase II study of vinorelbine (VRB) vs vindesine (VDS) in previously untreated non-small cell lung cancer (NSCLC) (abstract 1071). Proc Am Soc Clin Oncol 14:353
14.
Mori K, Kamiyama Y, Kondoh T, Tominaga K (2002) Phase II study of combined vinorelbine plus cisplatin for advanced non-small cell lung cancer (an interim report). Jpn Cancer Chemother 29:405–410
15.
Potier P (1989) The synthesis of navelbine prototype of a new series of vinblastine derivatives. Semin Oncol 16 [Suppl 4]:2–4
16.
Simon R (1989) Optimal two-stage designs for phase II clinical trial. Control Clin Trial 10:1–10PubMed
17.
Wozniak AJ, Crowley JJ, Balcerzak SP, et al (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16:2459–2465PubMed
Metadata
Title
Phase II study of the combination of vinorelbine and cisplatin in advanced non-small-cell lung cancer
Authors
Kiyoshi Mori
Yukari Kamiyama
Tetsuro Kondo
Yasuhiko Kano
Keigo Tominaga
Publication date
01-02-2004
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2004
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-003-0707-8

Other articles of this Issue 2/2004

Cancer Chemotherapy and Pharmacology 2/2004 Go to the issue

Original Article

Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma

Original Article

LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice

Original Article

The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice

Original Article

Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase

Original Article

A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer

Original Article

Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits